Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating safety, tolerability, pharmacokinetics and efficacy of two different rates of subcutaneous treprostinil dose titration in pulmonary a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: WITHDRAWN